Theravance Biopharma (NASDAQ:TBPH) Earns Hold Rating from JonesTrading

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “hold” rating reissued by JonesTrading in a research note issued to investors on Monday,Benzinga reports.

A number of other research analysts have also commented on the stock. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday. TD Cowen increased their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. Weiss Ratings lowered Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. One investment analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $21.40.

Theravance Biopharma Trading Down 2.5%

Shares of Theravance Biopharma stock traded down $0.43 on Monday, reaching $17.20. The stock had a trading volume of 1,623,650 shares, compared to its average volume of 530,941. The business’s 50 day moving average is $16.56 and its two-hundred day moving average is $17.30. Theravance Biopharma has a 1 year low of $10.82 and a 1 year high of $21.03. The company has a market cap of $886.45 million, a P/E ratio of 7.82 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of $17.70 million for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, equities analysts anticipate that Theravance Biopharma will post 1.54 EPS for the current fiscal year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC purchased a new position in shares of Theravance Biopharma during the 1st quarter valued at about $900,000. Bank of America Corp DE boosted its stake in Theravance Biopharma by 78.2% in the first quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after buying an additional 82,978 shares in the last quarter. California State Teachers Retirement System boosted its stake in Theravance Biopharma by 1,649.4% in the first quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock worth $662,000 after buying an additional 38,431 shares in the last quarter. Quantinno Capital Management LP grew its position in Theravance Biopharma by 32.9% during the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 4,463 shares during the last quarter. Finally, Rangeley Capital LLC bought a new position in Theravance Biopharma during the first quarter valued at approximately $1,672,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.